Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation.
primary care
public health
qualitative research
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
18 11 2020
18 11 2020
Historique:
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
7
4
2021
Statut:
epublish
Résumé
The increasing incidence of chronic liver disease (CLD) in the UK may be attributed to a rise in preventable risk factors, including hazardous alcohol use and type 2 diabetes. Transient elastography (TE) can rapidly stratify risk of CLD in primary care populations and provide an opportunity to raise patient awareness of risk factors.This study explores patients' experiences of TE screening in a primary care setting. In addition, patient awareness of CLD risk is explored. This study used a qualitative process evaluation of a community screening pathway for CLD (Nottingham, UK). Participants completed semistructured interviews, which were audio-recorded, transcribed verbatim and analysed thematically. Twenty adults were purposively recruited 6 months to 2 years after TE screening. Inclusion criteria included (1) hazardous alcohol use, (2) type 2 diabetes and/or (3) persistently elevated liver enzymes without known cause. Undergoing TE in primary care was seen as acceptable to most participants. Hazardous alcohol use was identified as the primary cause of CLD; no participants were aware of metabolic risk factors. TE improved understanding of personal risk factors and prompted contemplation of lifestyle changes across all TE stratifications. However, participants' perceptions of risk were altered by the healthcare providers' communication of TE scores. High acceptability of TE, regardless of the risk factor, provides strong support for inclusion of TE stratification in primary care. Findings highlight the positive impact of receiving TE on risk awareness. Future clinical iterations should improve the structure and communication of TE results to patients.
Identifiants
pubmed: 33208336
pii: bmjopen-2020-041574
doi: 10.1136/bmjopen-2020-041574
pmc: PMC7677335
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e041574Subventions
Organisme : Medical Research Council
ID : MR/P008348/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Références
J Clin Gastroenterol. 2015 Jan;49(1):e6-e10
pubmed: 24440943
J Gastrointestin Liver Dis. 2008 Dec;17(4):389-94
pubmed: 19104698
Alcohol Alcohol. 2016 Sep;51(5):593-601
pubmed: 27155021
Lancet. 2018 Mar 17;391(10125):1097-1107
pubmed: 29198562
Lancet. 2014 Nov 29;384(9958):1953-97
pubmed: 25433429
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
BMJ Open. 2015 May 03;5(4):e007516
pubmed: 25941185
J Hepatol. 2012 Dec;57(6):1305-11
pubmed: 22871499
Hepatology. 2018 Jan;67(1):134-144
pubmed: 28859228
Addict Behav Rep. 2018 Aug 04;8:85-94
pubmed: 30140728
Hepatology. 2016 Dec;64(6):1969-1977
pubmed: 27301913
Prev Med. 2002 Feb;34(2):215-20
pubmed: 11817917
Intern Med J. 2013 Mar;43(3):247-53
pubmed: 22646061
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Int J Drug Policy. 2015 Oct;26(10):984-91
pubmed: 26256938
J Hepatol. 2014 Feb;60(2):282-9
pubmed: 24128415
Frontline Gastroenterol. 2020 Feb 10;11(2):86-92
pubmed: 32066993
Health Technol Assess. 2009 Apr;13(25):iii-iv, ix-xi, 1-134
pubmed: 19413926
BMJ. 2008 Mar 15;336(7644):598-600
pubmed: 18326503
Gut. 2018 Jan;67(1):6-19
pubmed: 29122851
Soc Sci Med. 2006 Nov;63(9):2418-28
pubmed: 16814441
J Hepatol. 2019 Dec;71(6):1141-1151
pubmed: 31470067
Sociol Health Illn. 2012 May;34(4):481-96
pubmed: 22034902
United European Gastroenterol J. 2018 Nov;6(9):1372-1379
pubmed: 30386610